查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1813355

IVF遗传风险评分市场预测（至2032年）：按测试类型、技术、应用、最终用户和地区进行的全球分析

IVF Genetic Risk Scoring Market Forecasts to 2032 - Global Analysis By Test Type (Single-Gene Risk Scoring, Polygenic Risk Scoring, Carrier Screening Panels and Whole Genome Sequencing), Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球 IVF 遗传风险评分市场预计在 2025 年达到 3.632 亿美元，到 2032 年将达到 8.813 亿美元，预测期内的复合年增长率为 13.5%。

体外受精（IVF）遗传风险评分（GRS）是一项尖端生殖技术，用于评估体外受精（IVF）胚胎的遗传健康状况。透过分析特定的遗传标记、单核苷酸多态性（SNP）和多基因风险因素，GRS可以预测胚胎未来患有特定遗传疾病或病症的可能性。此评分系统使临床医生和准父母能够做出明智的胚胎选择决策，从而提高健康怀孕的几率并降低遗传疾病的风险。 IVF GRS整合了先进的基因组学、生物资讯学和生殖医学技术，以更高的精准度和预测性提供个人化的不孕症治疗。

生殖技术的进步

基因组学、生物资讯学和胚胎筛检领域的快速创新推动了IVF遗传风险评分（GRS）的普及。多基因风险因子和单核苷酸多态性（SNP）检测技术的提升，使临床医生能够更有信心地进行个人化胚胎选择。人工智慧主导的分析技术与新一代定序（NGS）平台的整合进一步提高了预测准确性，使GRS成为现代不孕症治疗的基石。这些进步透过改善临床疗效和降低遗传性疾病的发病率，推动了市场扩张。

高成本且可近性有限

高成本和有限的可及性严重阻碍了IVF基因风险评分市场的成长。这些障碍将大量人群排除在早期基因组筛检之外，并阻碍了公平的医疗创新。新兴地区缺乏保险覆盖和基础设施，进一步加剧了差距，抑制了需求，并减缓了临床整合。因此，市场扩张仍受到限制，其变革潜力在服务不足的地区仍未充分发挥。

遗传性疾病发生率不断上升

囊肿纤维化、泰-萨克斯病和BRCA相关癌症等遗传性疾病的发生率不断上升，加剧了对预测性胚胎筛检的需求。 IVF遗传风险评分提供了一个主动的解决方案，能够及早识别遗传易感性，从而改善生殖决策。随着临床医生和准父母意识的不断增强，GRS有望成为生育治疗通讯协定的标准组成部分。这种日益增长的临床需求代表着巨大的成长机会，尤其是在遗传疾病高发生率地区。

胚胎受损的风险

基因检测过程中胚胎损伤的风险严重削弱了人们对体外受精（IVF）遗传风险评分的信心，阻碍了临床医生和准父母的采用。对侵入性切片检查技术及其对可存活胚胎的潜在危害的担忧引发了伦理和安全方面的担忧，阻碍了监管部门的核准和投资者的兴趣。这种不确定性阻碍了市场成长，限制了临床整合，并加剧了公众的怀疑，尤其是在生育政策保守、基因组学素养较低的地区。

COVID-19的影响

新冠疫情扰乱了体外受精（IVF）基因风险评分市场，扰乱了生育治疗，推迟了胚胎移植，并增加了患者的心理压力。诊所在关闭期间暂停运营，导致周期延迟和需求减少。然而，这场危机加速了人们对数位化咨商和基因组筛检的认知，刺激了长期成长。随着服务恢復，人们对个人化胚胎选择和基因分析的兴趣日益浓厚，推动了市场復苏和创新。

预测期内，性状筛检部分预计将成为最大的部分

预测期内，性状筛检细分市场预计将占据最大市场份额，这得益于其在评估多基因风险和遗传疾病方面广泛的临床效用。透过分析特定基因标记，可以早期发现与慢性疾病、认知障碍和身体异常相关的性状。它是一种非侵入性技术，适用于现有的体外受精 (IVF) 工作流程，因此具有高度的扩充性。随着个人化医疗的兴起，性状筛检正成为胚胎选择的重要组成部分，并推动其占据主导的市场份额。

预计在预测期内，不孕症治疗诊所部门的复合年增长率最高。

由于对综合生殖健康服务的需求不断增长，预计生育诊所细分市场将在预测期内呈现最高成长率。这些诊所提供端到端的IVF解决方案，包括遗传咨询、胚胎筛检和个人化治疗方案。采用先进的GRS平台将改善患者预后并提高临床效率。随着人们对遗传风险评分的认识不断提高，生育诊所正逐渐成为一个重要的销售管道，尤其是在患者数量众多且实验室设备先进的都市区。

比最大的地区

在预测期内，由于生育治疗基础设施的不断扩大、人们对遗传疾病的认识不断提高以及政府的支持政策，预计亚太地区将占据最大的市场份额。由于人口结构的变化和中阶经济实力的不断增强，中国、印度和日本等国家正在越来越多地采用体外受精 (IVF)。区域性对基因组学和数位健康的投资正在进一步加速IVF GRS的整合。领先的生育诊所和研究机构的存在使亚太地区成为全球IVF GRS领域的主导力量。

复合年增长率最高的地区：

预计北美将在预测期内呈现最高的复合年增长率。这得益于其强大的医疗基础设施、较高的患者认知度以及对基因检测强有力的监管支持。该地区率先采用精准医疗和先进的体外受精 (IVF)通讯协定，为 GRS 的扩张提供了肥沃的土壤。生物技术公司与生育中心之间的策略联盟正在推动创新和可及性。优惠的报销政策和对个人化生殖医学日益增长的需求预计将使北美在市场成长方面保持领先地位。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球 IVF 遗传风险评分市场（依测试类型）

  • 单基因风险评分
  • 多基因风险评分
  • 承运人筛检小组
  • 全基因组序列分析

6. 全球 IVF 遗传风险评分市场（依技术）

  • NGS（次世代定序）
  • 微阵列
  • 基于PCR的方法
  • 人工智慧和机器学习演算法

7. 全球 IVF 遗传风险评分市场（按应用）

  • 胚胎选择
  • 疾病风险预测
  • 房产筛检
  • 个人化试管婴儿通讯协定
  • 其他用途

8. 全球 IVF 遗传风险评分市场（依最终用户）

  • 不孕不育诊所
  • 体外受精中心
  • 遗传咨询公司
  • 研究机构

9. 全球 IVF 遗传风险评分市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Natera, Inc.
  • CooperSurgical, Inc.
  • Thermo Fisher Scientific, Inc.
  • Vitrolife AB
  • Igenomix
  • Genea Limited
  • PerkinElmer, Inc.
  • Quest Diagnostics Incorporated
  • Invicta Genetics
  • Juno Genetics, US Inc.
  • Bioarray SL
  • Reproductive Health Science Ltd.
  • Genesis Genetics Ltd.
Product Code: SMRC30802

According to Stratistics MRC, the Global IVF Genetic Risk Scoring Market is accounted for $363.2 million in 2025 and is expected to reach $881.3 million by 2032 growing at a CAGR of 13.5% during the forecast period. IVF Genetic Risk Scoring (GRS) is a cutting-edge reproductive technology that evaluates the genetic health of embryos created through in vitro fertilization (IVF). By analyzing specific genetic markers, single-nucleotide polymorphisms (SNPs), and polygenic risk factors, GRS predicts the likelihood of an embryo developing certain inherited diseases or conditions later in life. This scoring system enables clinicians and prospective parents to make informed decisions about embryo selection, aiming to improve the chances of a healthy pregnancy and reduce the risk of genetic disorders. IVF GRS integrates advanced genomics, bioinformatics, and reproductive medicine to personalize fertility care with greater precision and foresight.

Market Dynamics:

Driver:

Advancements in Reproductive Technologies

Rapid innovations in genomics, bioinformatics, and embryo screening are propelling the adoption of IVF Genetic Risk Scoring (GRS). Enhanced precision in detecting polygenic risk factors and single-nucleotide polymorphisms (SNPs) enables clinicians to personalize embryo selection with greater confidence. Integration of AI-driven analytics and next-generation sequencing (NGS) platforms is further improving predictive accuracy, making GRS a cornerstone of modern fertility care. These advancements are driving market expansion by elevating clinical outcomes and reducing the incidence of inherited disorders.

Restraint:

High Cost and Limited Accessibility

High cost and limited accessibility significantly hinder the growth of the IVF genetic risk scoring market by restricting adoption to affluent urban centers. These barriers exclude vast populations from early-stage genomic screening, stalling equitable healthcare innovation. The lack of insurance coverage and infrastructure in emerging regions further exacerbates disparities, curbing demand and slowing clinical integration. As a result, market expansion remains constrained, with transformative potential unrealized across underserved geographies.

Opportunity:

Rising Incidence of Genetic Disorders

The increasing prevalence of hereditary conditions such as cystic fibrosis, Tay-Sachs, and BRCA-related cancers is intensifying demand for predictive embryo screening. IVF Genetic Risk Scoring offers a proactive solution by enabling early identification of genetic predispositions, thereby improving reproductive decision-making. As awareness grows among clinicians and prospective parents, GRS is poised to become a standard component of fertility protocols. This rising clinical need presents a significant growth opportunity, especially in regions with high rates of inherited diseases.

Threat:

Risk of Embryo Damage

The risk of embryo damage during genetic testing significantly undermines confidence in IVF genetic risk scoring, deterring adoption among clinicians and prospective parents. Concerns over invasive biopsy techniques and potential harm to viable embryos raise ethical and safety alarms, stalling regulatory approvals and investor interest. This uncertainty hampers market growth, limits clinical integration, and fuels public skepticism, especially in regions with conservative reproductive policies and limited genomic literacy.

Covid-19 Impact

The COVID-19 pandemic disrupted the IVF Genetic Risk Scoring market by halting fertility treatments, delaying embryo transfers, and increasing emotional stress for patients. Clinics paused operations during lockdowns, leading to postponed cycles and reduced demand. However, the crisis accelerated digital consultations and genomic screening awareness, fostering long-term growth. As services resumed, heightened interest in personalized embryo selection and genetic profiling positioned the market for resilient recovery and innovation.

The trait screening segment is expected to be the largest during the forecast period

The trait screening segment is expected to account for the largest market share during the forecast period, due to its broad clinical utility in assessing polygenic risks and inherited conditions. By analyzing specific genetic markers, this segment enables early detection of traits linked to chronic diseases, cognitive disorders, and physical anomalies. Its non-invasive nature and compatibility with existing IVF workflows make it highly scalable. As personalized medicine gains traction, trait screening is becoming integral to embryo selection, driving its leadership in market share.

The fertility clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the fertility clinics segment is predicted to witness the highest growth rate, due to rising demand for integrated reproductive services. These clinics offer end-to-end IVF solutions, including genetic counseling, embryo screening, and personalized treatment plans. Their adoption of advanced GRS platforms enhances patient outcomes and boosts clinical efficiency. As awareness of genetic risk scoring grows, fertility clinics are emerging as key distribution channels, particularly in urban centers with high patient volumes and advanced lab capabilities.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its expanding fertility infrastructure, rising awareness of genetic disorders, and supportive government initiatives. Countries like China, India, and Japan are witnessing increased IVF adoption, driven by demographic shifts and growing middle-class affordability. Regional investments in genomics and digital health are further accelerating GRS integration. The presence of leading fertility clinics and research institutions positions Asia Pacific as a dominant force in the global IVF GRS landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, high patient awareness, and strong regulatory support for genetic testing. The region's early adoption of precision medicine and advanced IVF protocols makes it fertile ground for GRS expansion. Strategic collaborations between biotech firms and fertility centers are enhancing innovation and accessibility. Favorable reimbursement policies and growing demand for personalized reproductive care are expected to sustain North America's leadership in market growth.

Key players in the market

Some of the key players profiled in the IVF Genetic Risk Scoring Market include Illumina, Inc., Agilent Technologies, Inc., Natera, Inc., CooperSurgical, Inc., Thermo Fisher Scientific, Inc., Vitrolife AB, Igenomix, Genea Limited, PerkinElmer, Inc., Quest Diagnostics Incorporated, Invicta Genetics, Juno Genetics, US Inc., Bioarray S.L., Reproductive Health Science Ltd. and Genesis Genetics Ltd.

Key Developments:

In July 2025, Thermo Fisher Scientific has agreed to acquire Sanofi's sterile manufacturing site in Ridgefield, New Jersey. This expansion aims to bolster U.S. drug product manufacturing capabilities, enhancing capacity to meet the increasing demand from pharmaceutical and biotech customers.

In July 2020, PerkinElmer partnered with Sonora Quest Laboratories to expand COVID-19 testing in Arizona. This collaboration aimed to increase testing capacity in response to rising case numbers, supported by funding from the state of Arizona.

Test Types Covered:

  • Single-Gene Risk Scoring
  • Polygenic Risk Scoring
  • Carrier Screening Panels
  • Whole Genome Sequencing

Technologies Covered:

  • NGS (Next-Generation Sequencing)
  • Microarray
  • PCR-Based Methods
  • AI & Machine Learning Algorithms

Applications Covered:

  • Embryo Selection
  • Disease Risk Prediction
  • Trait Screening
  • Personalized IVF Protocols
  • Other Applications

End Users Covered:

  • Fertility Clinics
  • IVF Centers
  • Genetic Counseling Firms
  • Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global IVF Genetic Risk Scoring Market, By Test Type

  • 5.1 Introduction
  • 5.2 Single-Gene Risk Scoring
  • 5.3 Polygenic Risk Scoring
  • 5.4 Carrier Screening Panels
  • 5.5 Whole Genome Sequencing

6 Global IVF Genetic Risk Scoring Market, By Technology

  • 6.1 Introduction
  • 6.2 NGS (Next-Generation Sequencing)
  • 6.3 Microarray
  • 6.4 PCR-Based Methods
  • 6.5 AI & Machine Learning Algorithms

7 Global IVF Genetic Risk Scoring Market, By Application

  • 7.1 Introduction
  • 7.2 Embryo Selection
  • 7.3 Disease Risk Prediction
  • 7.4 Trait Screening
  • 7.5 Personalized IVF Protocols
  • 7.6 Other Applications

8 Global IVF Genetic Risk Scoring Market, By End User

  • 8.1 Introduction
  • 8.2 Fertility Clinics
  • 8.3 IVF Centers
  • 8.4 Genetic Counseling Firms
  • 8.5 Research Institutes

9 Global IVF Genetic Risk Scoring Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Illumina, Inc.
  • 11.2 Agilent Technologies, Inc.
  • 11.3 Natera, Inc.
  • 11.4 CooperSurgical, Inc.
  • 11.5 Thermo Fisher Scientific, Inc.
  • 11.6 Vitrolife AB
  • 11.7 Igenomix
  • 11.8 Genea Limited
  • 11.9 PerkinElmer, Inc.
  • 11.10 Quest Diagnostics Incorporated
  • 11.11 Invicta Genetics
  • 11.12 Juno Genetics, US Inc.
  • 11.13 Bioarray S.L.
  • 11.14 Reproductive Health Science Ltd.
  • 11.15 Genesis Genetics Ltd.

List of Tables

  • Table 1 Global IVF Genetic Risk Scoring Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 3 Global IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 4 Global IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 5 Global IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 6 Global IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 7 Global IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 8 Global IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 9 Global IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 10 Global IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 11 Global IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 12 Global IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 13 Global IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 14 Global IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 15 Global IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 16 Global IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 17 Global IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 18 Global IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 19 Global IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 20 Global IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 21 Global IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 22 Global IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 23 North America IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 24 North America IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 25 North America IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 26 North America IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 27 North America IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 28 North America IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 29 North America IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 30 North America IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 31 North America IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 32 North America IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 33 North America IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 34 North America IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 35 North America IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 36 North America IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 37 North America IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 38 North America IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 39 North America IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 40 North America IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 41 North America IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 42 North America IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 43 North America IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 44 North America IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 45 Europe IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 46 Europe IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 47 Europe IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 48 Europe IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 49 Europe IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 50 Europe IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 51 Europe IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 52 Europe IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 53 Europe IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 54 Europe IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 55 Europe IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 56 Europe IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 57 Europe IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 58 Europe IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 59 Europe IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 60 Europe IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 61 Europe IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 62 Europe IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 63 Europe IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 64 Europe IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 65 Europe IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 66 Europe IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 67 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 68 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 69 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 70 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 71 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 72 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 73 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 74 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 75 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 76 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 77 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 78 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 79 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 80 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 81 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 82 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 83 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 84 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 85 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 86 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 87 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 88 Asia Pacific IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 89 South America IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 90 South America IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 91 South America IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 92 South America IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 93 South America IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 94 South America IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 95 South America IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 96 South America IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 97 South America IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 98 South America IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 99 South America IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 100 South America IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 101 South America IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 102 South America IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 103 South America IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 104 South America IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 105 South America IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 106 South America IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 107 South America IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 108 South America IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 109 South America IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 110 South America IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 111 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Country (2024-2032) ($MN)
  • Table 112 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Test Type (2024-2032) ($MN)
  • Table 113 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Single-Gene Risk Scoring (2024-2032) ($MN)
  • Table 114 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Polygenic Risk Scoring (2024-2032) ($MN)
  • Table 115 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Carrier Screening Panels (2024-2032) ($MN)
  • Table 116 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Whole Genome Sequencing (2024-2032) ($MN)
  • Table 117 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Technology (2024-2032) ($MN)
  • Table 118 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By NGS (Next-Generation Sequencing) (2024-2032) ($MN)
  • Table 119 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Microarray (2024-2032) ($MN)
  • Table 120 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By PCR-Based Methods (2024-2032) ($MN)
  • Table 121 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By AI & Machine Learning Algorithms (2024-2032) ($MN)
  • Table 122 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Application (2024-2032) ($MN)
  • Table 123 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Embryo Selection (2024-2032) ($MN)
  • Table 124 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Disease Risk Prediction (2024-2032) ($MN)
  • Table 125 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Trait Screening (2024-2032) ($MN)
  • Table 126 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Personalized IVF Protocols (2024-2032) ($MN)
  • Table 127 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 128 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By End User (2024-2032) ($MN)
  • Table 129 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Fertility Clinics (2024-2032) ($MN)
  • Table 130 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By IVF Centers (2024-2032) ($MN)
  • Table 131 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Genetic Counseling Firms (2024-2032) ($MN)
  • Table 132 Middle East & Africa IVF Genetic Risk Scoring Market Outlook, By Research Institutes (2024-2032) ($MN)